Fuxia Li

机构：First Affiliated Hospital of Shihezi University Medical College

发表论文 5 篇 · 总被引 40 次 · h-index 3

代表论文

• miR-369 inhibits Liver Cancer progression by targeting ZEB1 pathway and predicts the prognosis of HCC patients (2021 · Journal of Cancer · 被引 17)
• The Real-world Therapeutic Analysis of First-line Immunotherapy in Chinese Patients with Drive Gene Positive for Advanced Non-Small Cell Lung Cancer (2023 · Journal of Cancer · 被引 16)
• Serum iron element: A novel biomarker for predicting PD-1 immunotherapy efficacy (2024 · International Immunopharmacology · 被引 5)
• Visual analysis of ovarian cancer immunotherapy: a bibliometric analysis from 2010 to 2025 (2025 · Frontiers in Medicine · 被引 2)
• Corrigendum to “Serum iron element: A novel biomarker for predicting PD-1 immunotherapy efficacy” [Int. Immunopharmacol. 131 (2024) 111823] (2024 · International Immunopharmacology)